www.stocktitan.net
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) reported that its Board Compensation Committee granted Nasdaq Listing Rule 5635(c)(4) inducement equity awards under the 2024 Inducement Plan on August 3–4, 2026. The grants include non-qualified stock options for 63,011 shares and RSUs for 44,987 shares to new Chief Regulatory Officer Nancy Bowman, M.D., Ph.D., and options for 5,600 shares plus RSUs for 2,800 shares to two new employees.Options granted on August 3 have an exercise price of $32.23 per share, and those granted on August 4 have a $29.95 exercise price. Options vest over four years with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually on each August 20 over four years, all subject to continued service and award agreements.